Caspase-7 is a caspase involved in the execution phase of apoptosis. To explore the possibility that the genetic alterations of CASPASE-7 might be involved in the development of human cancers, we analysed the entire coding region and all splice sites of human CASPASE-7 gene for the detection of somatic mutations in a series of human solid cancers, including carcinomas from stomach, colon, head/neck, esophagus, urinary bladder and lung. Overall, we detected CASPASE-7 mutations in two of 98 colon carcinomas (2.0%), one of 50 esophageal carcinomas (2.0%) and one of 33 head/neck carcinomas (3.0%). We expressed the tumor-derived caspase-7 mutants in 293 T cells and found that the apoptosis was reduced compared to the wild-type caspase-7. This is the first report on the CASPASE-7 gene mutations in human malignancies, and our data suggest that the inactivating mutations of the CASPASE-7 gene might lead to the loss of its apoptotic function and contribute to the pathogenesis of some human solid cancers. Oncogene (2003 Oncogene ( ) 22, 8048-8052. doi:10.1038 Keywords: CASPASE-7; mutation; solid cancer; apoptosis; caspases Apoptosis is a fundamental biochemical cell-death pathway essential for normal tissue homeostasis, cellular differentiation and development (Reed, 2000) . Proteases cause the morphological changes that are recognized as apoptosis and the biochemical changes associated with apoptosis (Nicholson, 1999) . Among the proteases, a family of cysteine proteases that cleave the substrates at aspartate residues, known as caspases, plays a main role during apoptosis (Nicholson, 1999; Reed, 2000) . The caspase gene family thus far contains at least 14 mammalian members, of which 12 human enzymes are known (Nicholson, 1999) . From a functional perspective, the caspase gene family has been classified into either initiator caspases or effector caspases. The initiator caspases would appear to be caspase-2, -8, -9 and -10, and the effector caspases would appear to be caspase-3, -6 and -7 (Nicholson, 1999) . The effector caspases are thought to be responsible for the actual destruction of the cell. Caspase-7 is highly related to caspase-3, and these two caspases are activated by both death receptor-and mitochondria-induced apoptosis (Tewari et al., 1995; Duan et al., 1996; Pai et al., 1996; Lippke et al., 1996; Slee et al., 2001 ). The initiator caspases-8 and -9 can process pro-caspase-7 by cleavage, giving rise to p23 and p12 subunits (Hirata et al., 1998; Slee et al., 1999) .
It is now believed that clonal expansion and tumor growth are the results of the deregulation of intrinsic proliferation (cell division) and cell death (apoptosis) (Hanahan and Weinberg, 2000) . Failure of apoptosis could allow the survival of transformed cells that are prone to undergo further genetic damage and play an important role in the pathogenesis of tumors. Either inactivation of proapoptotic pathway or activation of antiapoptotic pathway results in failure of apoptosis, thereby promoting tumor cell survival. There has been evidence that alterations of caspases participate in tumor development (Mandruzzato et al., 1997; Kurokawa et al., 1999; Lee et al., 1999; Schwartz et al., 1999; Palmerini et al., 2001; Shin et al., 2002) . In vitro studies showed that resistance to apoptosis in some cancer cell lines correlates with losses of caspases (Kurokawa et al., 1999) . Also, an immunohistochemical study revealed downregulation of caspase-7 in colon cancer samples compared with normal colon mucosa (Palmerini et al., 2001) . In addition, epigenetic modification of CASPASE-8 by DNA methylation has recently been implied in loss of caspase-8 function in several solid tumors of childhood (Teitz et al., 2000; Fulda et al., 2001) . Mutations of the genes involved in apoptosis, including the death receptors and caspases, have been reported in human cancers, implying that the somatic mutations of apoptosis-related genes may not be a rare event in the cancer pathogenesis (Mandruzzato et al., 1997; Kurokawa et al., 1999; Lee et al., 1999; Schwartz et al., 1999; Shin et al., 2002) . Among the caspases, somatic mutations of CASPASE-3, -5, -8 and -10 have been reported in human cancer tissues and cell lines (Mandruzzato et al., 1997; Kurokawa et al., 1999; Schwartz et al., 1999; Fulda et al., 2001; Shin et al., 2002) . Most of the caspase mutations detected in human cancers showed reduced apoptosis activities compared to the wild-type caspases (Mandruzzato et al., 1997; Kurokawa et al., 1999; Shin et al., 2002) , suggesting that inhibition of the apoptosis by the mutations might play an important role in the tumorigenesis. To date, the data on the somatic mutations of CASPASE-7 are lacking. In the present study, to explore the possibility that the alterations of the CASPASE-7 gene might play a role in the development of solid cancers, we analysed a series of human solid cancers for detection of somatic mutations of CASPASE-7 gene.
Formalin-fixed tissues of 33 head/neck squamous cell carcinomas, 35 transitional cell carcinomas of urinary bladder, 50 esophageal squamous cell carcinomas and 80 nonsmall cell lung cancers, and methacarn-fixed tissues of 98 colon adenocarcinomas and 50 gastric adenocarcinomas were selected for this study. Approval was obtained from the Catholic University of Korea, College of Medicine's institutional review board for this study. Informed consent was provided according to the Declaration of Helsinki. Malignant cells and corresponding normal cells from the same patients were selectively procured from hematoxylin and eosin-stained slides using a 30G1/2 hypodermic needle (Becton Dickinson, Franklin Lakes, NJ, USA) affixed to a micromanipulator, as described previously (Lee et al., 1998) . Genomic DNA was isolated and analysed for potential mutations in the six exons in the coding region and all splice sites of the CASPASE-7a gene by PCR-SSCP analysis. Enrichment and direct sequence analysis of aberrantly migrating bands led to the identification of mutations in four of the 336 samples (1.2%) ( Table 1 and Figure 1 ). The mutations consisted of one missense mutation in a head/neck squamous cell carcinoma, one nonsense mutation in a colon adenocarcinoma (rectum) and one silent mutation in a colon adenocarcinoma (ascending colon) and one splice-site mutation in an esophageal squamous cell carcinoma. The missense mutation, identified in exon 2, would result in the substitution of Cys by Tyr at amino-acid residue 70 (Cys 70 Tyr) at the p20 large protease subunit. The nonsense mutation, identified in exon 2, showed a point mutation introducing a premature termination signal at codon 43 (Arg 43 stop) at the p23 large protease subunit. The splicesite mutation affected position À3 of the consensus sequence of the acceptor splice site of intron 1. None of the corresponding normal samples showed evidence of mutations by SSCP (Figure 1 ), indicating the mutations detected in the tumor specimens had risen somatically. We repeated the experiments three times, including tissue microdissection, PCR, SSCP and sequencing analysis to ensure the specificity of the results, and found that the data were consistent (data not shown).
For the allelic status of CASPASE-7 in the cancers, we have analysed biallelic polymorphisms at nucleotide position 633 C/G (exon 6) and 648 G/A (exon 6), which have been found in the Genbank database. SSCP analysis at these polymorphic sites was used for the detection of LOH as well as for the detection of mutations. Complete or nearly complete absence of one allele in tumor DNA of informative cases, as defined by the direct visualization, was considered as LOH (Lee et al. 1998; 1999) . With the polymorphism 633 C/G, 15.1% of the cases were informative and 45.1% of the informative cases showed LOH, while with the polymorphism 648 G/A, 7.1% of the cases were informative and 54.1% of the informative cases showed LOH. However, unfortunately, all of the cases with CAS-PASE-7 mutation were noninformative or showed retention of heterozygosity ( Figure 1 , Table 1 ).
To determine whether the mutant forms of caspase-7 are functionally defective, we generated caspase-7 mammalian expression constructs containing the mutations (Cys 70 Tyr and Arg 43 stop) found in this study by using site-directed mutagenesis. Since the earlier studies (Duan et al., 1996) described that the overexpression of full-length human caspase-7 failed to induce apoptosis, but the expression of a truncated derivative of caspase-7, which lacks N-terminal 9 amino acids including a prodomain and a part of a large subunit of CASPASE-7a, caused apoptosis, we used GFP-caspase-7 fusion proteins lacking the N-terminal 9 amino acids in CASPASE-7a. On transfection into 293 T cells, we found that both of the mutants showed a significant defect in apoptosis function compared to the wild type (Figure 2a ; Dunnett's multiple comparison test, Po0.001). The decrease of apoptosis by the mutants was proportional to the amount of mutant plasmids used (Figure 2a) . Parts of the lysates derived from these transfected cells were also analysed directly by immunoblotting as a control to verify production of Numbering of cDNA of CASPASE-7 was done in respect to the ATG start codon CASPASE-7 mutations in human cancers YH Soung et al each protein. Furthermore, to explore how the caspase-7 mutants impair apoptosis, we coexpressed each inactivating caspase-7 mutant either with Fas or tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2), and found that these mutants interfered the death induction by Fas, but not by TRAIL-R2 overexpression, indicating that these mutants have dominant-negative inhibition of the Fasinduced apoptosis (Figure 2b ; Dunnett's multiple comparison test, Po0.001).
We analysed caspase-7 protein expressions in the tissue sections of the four cases with CASPASE-7 mutations by immunohistochemistry with caspase-7 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The cancer cells in all of the four cases showed immunoreactivity for caspase-7. However, the caspase-7 immunostainings in the esophageal squamous cell carcinoma (Eso 1) and the laryngeal squamous cell carcinoma (HN 25) were weaker than those of the colon cancers (Col 41 and Col 113) (Figure 3) .
The aim of the present study was to address whether human solid cancers have CASPASE-7 gene mutations. If so, the next aim was to address whether the mutations inactivate the proapoptotic activity of caspase-7. We Figure 1 Mutations of CASPASE-7 gene in human cancers. Genomic DNA each from normal cells or tumor cells was amplified with eight primer pairs covering the entire coding region of CASPASE-7 gene. Radioisotope was incorporated into the PCR products for detection by autoradiogram. The PCR reaction mixture was denatured for 1 min at 941C and incubated for 35 cycles. Other procedures of PCR and SSCP analysis were performed as described previously . After SSCP, DNAs showing mobility shifts were cut out from the dried gel, and reamplified for 30 cycles using the same primer sets. Sequencing of the PCR products was carried out using the cyclic sequencing kit (Perkin-Elmer, Foster City, CA, USA) according to the manufacturer's recommendation. For the allelic status of CASPASE-7 in the cancers, we have analysed biallelic polymorphisms at nucleotide positions 633 C/G (exon 6) and 648 G/A (exon 6). The PCR and SSCP conditions of LOH study were the same as the conditions described above. SSCP (a, b, c and g) and sequencing analysis ( observed that several types of human solid cancers have CASPASE-7 gene mutations. Moreover, the transfection study revealed that the cancer-derived caspase-7 mutants showed a loss of apoptotic function. These data together with the earlier reports on the inactivating mutations of proapoptosis genes in human cancers (Mandruzzato et al., 1997; Kurokawa et al., 1999; Lee et al., 1999; Schwartz et al., 1999; Shin et al., 2002) indicate that somatic mutation of proapoptosis genes, including CASPASE-7, may be a frequent event in the pathogenesis of human cancers, and suggest that these mutations may play an important role in the apoptosis resistance of cancer cells. Caspase-7, like caspase-3, is present as an inactive proenzyme comprising a prodomain and a catalytic protease domain that can be further processed to give a large p23 and a small p12 subunit (Duan et al., 1996; Pai et al., 1996; Lippke et al., 1997) . Among the mutations of CASPASE-7 found in this study, one nonsense mutation (case Col 41) was identified in the coding regions of the large p23 subunit. The nonsense mutation is predicted to cause premature termination of protein synthesis, and hence resemble typical loss-of-function mutations. The C to T transition at bp 127 leads to a termination at codon 43, resulting in a protein that has a prodomain and a part of p23 large subunit. In addition, the Arg at amino acid 43 is conserved in caspase-7 among the species of human, mouse and rat (Genbank database). Also, this amino acid is conserved in other caspases such as caspase-3, -6, -8 and -9 (Genbank database). Previous structural analysis of caspases demonstrated that the residues constituting the binding pocket for P 1 Asp are conserved in the caspases and important for the apoptosis induction of the caspases (Boldin et al., 1996) . The Arg-43 of caspase-7 is one of the constituting residues for P 1 binding pocket (Chai et al., 2001) , and it seems that alteration of the Arg-43 decreases the protease function of caspase-7. Expression of this mutant confirmed that this mutant has a defect in induction of apoptosis (Figure 2) .
We also found one missense mutation (case HN 25) in the p23 large subunit. The predicted amino-acid change is substitution of Cys at amino acid 70 to Tyr. Of note, the Cys at amino acid 70 is conserved in the caspase-7 among the species of human, hamster, mouse and rat. Alteration in this conserved sequence together with the transfection data (Figure 2) suggests that the 70 Cys to Tyr mutant may lead a loss of apoptosis function of caspase-7 in the corresponding cancer in vivo. Regarding the splice-site mutation, mutations at the consensus sequence of acceptor site of intron have been shown to cause cryptic splice-site utilization and exon skipping in various human disease genes (Krawczak et al., 1992) . Thus, it is possible that the splice-site mutation observed in intron 1 (IVS 1 C -3 to T) might result in abnormal splicing of CASPASE-7 mRNA.
Previous LOH and karyotypic studies have suggested that a putative tumor-suppressor gene at chromosome 10q25 may be involved in the development of human cancers (Mitelman et al., 1997) . Several candidate tumor-suppressor genes of this region have been identified (Mollenhauer et al., 2001) . For example, deleted in malignant brain tumors 1 (DMBT1) gene in this locus has been proposed as a candidate tumorsuppressor gene for brain, lung and digestive tract cancer (Mollenhauer et al., 2001) . Whether CASPASE-7 gene is such a tumor suppressor is unknown at this time. However, in this study, LOH and mutation of CASPASE-7 were not highly frequent 
in human cancers, suggesting that CASPASE gene is not responsible for 10q25 LOH in human cancers. Once activated, the effector caspases are responsible for the proteolytic degradation of a broad spectrum of cellular targets that ultimately lead to cell death. Among the effector caspases, caspase-3 shares 54% sequence identity with caspase-7 (Duan et al., 1996; Pai et al., 1996; Lippke et al., 1997) ; these two caspases exhibit highly similar structures and function. However, a recent report demonstrated that effector caspase-3 and -7 perform distinct, nonredundant roles during the execution phase of apoptosis, suggesting that in cancer cell apoptosis caspase-3 and -7 also perform nonredundant roles in vivo and that abrogation of apoptosis by CASPASE-7 mutation might not be compensated by other caspases.
Several lines of evidence suggest that the loss of apoptosis function can enhance tumor development. For example, tumorigenesis driven by the Em-myc transgene was shown to be markedly accelerated in lpr mice with germline Fas mutation compared to wild-type mice, confirming a causal, rather than correlative, role for apoptosis loss in tumor development (Zo¨rnig et al., 1995) . In this study, we have shown another suggestion, namely that the possible apoptosis dysregulation due to the caspase-7 mutation may be involved in human solid cancer pathogenesis.
Abbreviations PCR, polymerase chain reaction; DAPI, 4 0 , 6-diamidine-2 0 -phenylindole dihydrochloride; GFP, green fluorescent protein; SSCP, single strand conformation polymorphism; LOH, loss of heterozygosity; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand.
